Navigation Links
Bavarian Nordic in Negotiations With the US Authorities for the Further Development of IMVAMUNE(R)
Date:8/24/2009

KVISTGAARD, Denmark, August 24 /PRNewswire-FirstCall/ -- Bavarian Nordic A/S (OMX: BAVA) announced today that the US authorities have initiated negotiations for a new contract to develop a freeze-dried version of the IMVAMUNE(R) smallpox vaccine. This potential new project will have no influence on the ongoing RFP-3 BARDA (Biomedical Advanced Research and Development Authority) contract for the procurement of 20 million doses of IMVAMUNE(R) and the licensure of the current liquid-frozen formulation, but represents an additional business opportunity.

Earlier this year BARDA published a Broad Agency Announcement (BAA) soliciting proposals for the advanced development of medical countermeasures against chemical, biological, radiological and nuclear (CBERN) threats. In June, Bavarian Nordic submitted a proposal for the development of a freeze-dried formulation of the MVA-based smallpox vaccine, IMVAMUNE(R). The proposal included the validation of the production process and the preclinical and clinical development to support the use of the new freeze-dried formulation of IMVAMUNE(R) following a declared emergency.

A freeze-dried formulation of IMVAMUNE(R) offers various new advantages in terms of increased shelf-life and improved stability of the vaccine compared to the current liquid-frozen formulation. Additionally, this will improve the cold-chain shipping logistics and storage. These are all important criteria for governments around the world that prioritise their bio terror preparedness.

The new technology for freeze-drying the vaccine will also be applicable for other MVA-BN(R) based vaccines.

Anders Hedegaard, President & CEO of Bavarian Nordic said: "We are happy about entering into negotiations with the US government on yet another RFP for IMVAMUNE(R). It clearly demonstrates their desire to expand the ongoing collaboration beyond the existing contract to deliver 20 mil
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
2. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
3. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
4. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
5. Bavarian Nordics Case Against Oxford BioMedica
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. Bavarian Nordic Publishes its Annual Results 2008
8. Bavarian Nordic Announces its Interim Report for the Period 1 January to 31 March 2009
9. The Court Supports Bavarian Nordics Decision to Start Patent Infringement Case Against Oxford BioMedica
10. National Stem Cell Holding in Final Stage Negotiations for Exclusive Licensing of its Recently Discovered Biomaterial for Anti-Aging Applications
11. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014   Niagara Thermal Products is proud ... BioBlower Technologies LLC ("B3") as the critical thermal component ... from the Army Corps of Engineers.  B3 has developed ... biological contaminants and destroys VOCs and other chemical pollutants, ...
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. – ... Warrington, Pa. , Details: The Hepatitis B Foundation, ... cure for hepatitis B and improving the quality of life ... on Friday, April 11 at Warrington Country Club in Warrington, ...
Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... Nets to Prevent Serious Health Hazards ... Associated with Diethylene ... Pharmacopeial (USP),Convention today announced a revised Glycerin monograph in ... United States. The,revision strengthens safety nets to prevent serious ...
... The following was issued,today by the Greater Baltimore ... CEO, Greater Baltimore Committee, 140 company owners, executives ... The third annual Greater Baltimore Region Bioscience Awards, ... / Breakfast & Registration, 8:45 - 9:30 a.m. ...
... March 17 Mercury Therapeutics,Inc. (MTI), a ... protein,kinase targeted drugs, announces that it has ... advise on its strategic and partnering,opportunities, with ... shareholders., This appointment follows a significant ...
Cached Biology Technology:USP Announces Revised Glycerin Monograph 2USP Announces Revised Glycerin Monograph 3Greater Baltimore Committee to Announce Winners of Third Baltimore Region Bioscience Awards at Ceremonies on March 18 2Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities 2Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities 3
(Date:7/9/2014)... of a sparrow-sized fossil from China challenges the commonly ... that gained the ability to fly. The birdlike fossil ... much rather the remains of a tiny tree-climbing animal ... the Dinosaur Museum in Blanding, Utah, and Alan Feduccia ... in Springer,s Journal of Ornithology . , The ...
(Date:7/9/2014)... results accrue. To completely and systematically archive this ... fact, researchers in the life sciences spend a ... an online survey of 70 people working in ... Applied Information Technology FIT in Sankt Augustin. Many ... centralized or structured approach to data collection in ...
(Date:7/9/2014)... in their blood are more likely to survive the disease, ... of vitamin D have half the risk of dying compared ... The study is the first to correlate total blood levels ... which includes that produced after exposure to sunlight and ... survival prospects. , The University of Edinburgh team tested ...
Breaking Biology News(10 mins):Researchers declassify dinosaurs as being the great-great-grandparents of birds 2Managing the data jungle 2Managing the data jungle 3
... addictive substance in cigarette smoke, contributes to smokers, higher ... attacks, according to research to be presented Sunday, Dec. ... Meeting in New Orleans. These findings suggest ... steam without the carcinogenic agents of tobacco smoke, may ...
... An experimental drug that targets macrophages, a type of ... tumor glioblastoma multiforme decreased the cancer,s growth and extended ... report on Tuesday Dec. 17, at the American Society ... The rates of apoptosis, or programmed cell death, ...
... A cross-sectional study by investigators from Tokyo University has ... factor against sarcopenia and effective in maintaining muscle strength ... the ageing process, resulting in loss of skeletal muscle ... The multiple adverse health outcomes include physical disability, poor ...
Cached Biology News:Nicotine drives cell invasion that contributes to plaque formation in coronary arteries 2Blocking tumor-associated macrophages decreased glioblastoma's growth & extended survival in mice 2
... UltraPure Agarose and SYBR Safe DNA Gel Stain ... Saves money versus buying these same products separately ... alternative to ethidium bromide ... Agarose resolves DNA and RNA fragments from 100 bp ...
Anti-WT-1 Liquid. In 10 μM PBS, 0.2 % BSA, pH 7.6. Recognizes the ~47-55 kDa Wilm's tumor protein in Wilm's tumor tissue. ...
... uses continuous chemical suppression and thermally stabilized ... accurate determinations of common anions and cations ... quick to equilibrate, and fully automated with ... you achieve maximum sample throughput at minimum ...
... siRNA applications, contains magnetic nanoparticles (MagTag) which ... of interest. Exploiting magnetic force the full ... towards and delivered into the target cells ... be used for adherent cells; for suspension ...
Biology Products: